Patents by Inventor Karsten Wassermann

Karsten Wassermann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions comprising balaglitazone and further antidiabetic compounds
    Publication number: 20090312350
    Abstract: Methods for treating conditions benefiting from a decrease in insulin resistance, a reduction of plasma glucose levels, a reduction of plasma fatty acid levels, a reduction of plasma triglyceride levels or reduction of VLDL levels comprising the administration of a composition consisting essentially of balaglitazone in combination with one or more dipeptidyl peptidase-IV inhibitors to a patient in need thereof.
    Type: Application
    Filed: August 21, 2009
    Publication date: December 17, 2009
    Inventors: Karsten Wassermann, Erik Max Wulff
  • Combined Use of Derivatives of GLP-1 Analogs and PPAR Ligands
    Publication number: 20070287669
    Abstract: The present invention provides methods and compositions for treatment and/or prevention of type 1 and type 2 diabetes, dyslipdemia, impaired glucose tolerance, insulin resistance, obesity, and beta-cell apoptosis, as well as methods for increasing the size and number of beta-cells in a subject and/or stimulating beta-cell proliferation, which comprise administering both a stable GLP-1 analogue and a non-thiazolidinedione PPAR ligand.
    Type: Application
    Filed: August 23, 2007
    Publication date: December 13, 2007
    Applicant: Novo Nordisk A/S
    Inventors: Liselotte Knudsen, Karsten Wassermann, Jeppe Sturis, Christian Brand, Carsten Gotfredsen
  • Compositions comprising balaglitazone and further antidiabetic compounds
    Publication number: 20070010423
    Abstract: Methods for the treatment of type 2 diabetes and related conditions comprising the admini-stration of balaglitazone in combination with one or more other antidiabetic compound is pro-vided together with combinations useful in said treatment.
    Type: Application
    Filed: June 24, 2004
    Publication date: January 11, 2007
    Inventors: Karsten Wassermann, Erik Wulff
  • Combined use of derivatives of GLP-1 analogs and PPAR ligands
    Publication number: 20050239707
    Abstract: The present invention provides methods and compositions for treatment and/or prevention of type 1 and type 2 diabetes, dyslipdemia, impaired glucose tolerance, insulin resistance, obesity, and beta-cell apoptosis, as well as methods for increasing the size and number of beta-cells in a subject and/or stimulating beta-cell proliferation, which comprise administering both a stable GLP-1 analogue and a non-thiazolidinedione PPAR ligand.
    Type: Application
    Filed: June 7, 2005
    Publication date: October 27, 2005
    Inventors: Liselotte Knudsen, Karsten Wassermann, Jeppe Sturis, Christian Brand
  • Use of estrogens and delta-gonadien-21-Ol-3,20-diones for treating insulin dependent and non-insulin dependent diabetes
    Patent number: 6555530
    Abstract: Analysis of full-blood glucose, serum insulin, serum triglycerides and total serum cholesterol were performed. Glucose levels in blood samples from the oral glucose tolerance test were used for calculation of the incremental Area Under the Curve (AUC0-120 min−baseline). All data are expressed as percentage change of vehicle treated animals (cf. FIGS. 1 and 2).
    Type: Grant
    Filed: January 31, 2000
    Date of Patent: April 29, 2003
    Assignee: Novo Nordisk A/S
    Inventor: Karsten Wassermann
  • Combined use of derivatives of GLP-1 analogs and PPAR ligands
    Publication number: 20030022816
    Abstract: The present invention provides methods and compositions for treatment and/or prevention of type 1 and type 2 diabetes, dyslipdemia, impaired glucose tolerance, insulin resistance, obesity, and beta-cell apoptosis, as well as methods for increasing the size and number of beta-cells in a subject and/or stimulating beta-cell proliferation, which comprise administering both a stable GLP-1 analogue and a non-thiazolidinedione PPAR ligand.
    Type: Application
    Filed: September 7, 2001
    Publication date: January 30, 2003
    Inventors: Liselotte Bjerre Knudsen, Karsten Wassermann, Jeppe Sturis, Christian Lehn Brand
  • Combined use of derivatives of GLP-1 analogs and PPAR ligands
    Publication number: 20020187926
    Abstract: The present invention provides methods and compositions for treatment and/or prevention of type 1 and type 2 diabetes, dyslipdemia, impaired glucose tolerance, insulin resistance, obeity, and beta-cell apoptosis, as well as methods for increasing the size and number of beta-cells in a subject and/or stimulating beta-cell proliferation, which comprise administering both a stable GLP-1 analogue and a non-thiazolidinedione PPAR ligand.
    Type: Application
    Filed: September 13, 2001
    Publication date: December 12, 2002
    Inventors: Liselotte Bjerre Knudsen, Karsten Wassermann, Jeppe Sturis, Christian Lehn Brand
  • Use of estrogens and delta-gonadien-21-3,20-diones
    Publication number: 20020028793
    Abstract: The present invention relates to the use of estrogens and delta-gonadien-21-ol-3,20-diones in the treatment or prophylaxis of hyperlipoproteinemia, hypertriglyceridemia, hyperlipidemia or hypercholesterolemia or arteriosclerosis or for anticoagulative treatment.
    Type: Application
    Filed: January 18, 2000
    Publication date: March 7, 2002
    Inventor: Karsten Wassermann